Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Nuclear Medicine Radioisotopes Market

ID: MRFR/HC/41433-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026
Nuclear Medicine Radioisotopes Market Research Report By Application (Diagnostic Imaging, Therapeutic Applications, Research Applications, Radiopharmaceutical Production), By Type (Alpha Emitters, Beta Emitters, Gamma Emitters, Positron Emitters), By End Use (Hospitals, Diagnostic Centers, Research Institutions), By Radiopharmaceutical Form (Injectable, Oral, Inhalation) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Billion) | |
      1. 4.1.1 Diagnostic Imaging | |
      2. 4.1.2 Therapeutic Applications | |
      3. 4.1.3 Research Applications | |
      4. 4.1.4 Radiopharmaceutical Production |
    2. 4.2 Healthcare, BY Type (USD Billion) | |
      1. 4.2.1 Alpha Emitters | |
      2. 4.2.2 Beta Emitters | |
      3. 4.2.3 Gamma Emitters | |
      4. 4.2.4 Positron Emitters |
    3. 4.3 Healthcare, BY End Use (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Diagnostic Centers | |
      3. 4.3.3 Research Institutions |
    4. 4.4 Healthcare, BY Radiopharmaceutical Form (USD Billion) | |
      1. 4.4.1 Injectable | |
      2. 4.4.2 Oral | |
      3. 4.4.3 Inhalation |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 GE Healthcare (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Siemens Healthineers (DE) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bayer AG (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Cardinal Health (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Elekta AB (SE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Lantheus Medical Imaging (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 NorthStar Medical Radioisotopes (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Radiopharma (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Bracco Imaging (IT) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies | |
      10. 5.2.10 Iba Group (BE) | | |
        1. 5.2.10.1 Financial Overview | | |
        2. 5.2.10.2 Products Offered | | |
        3. 5.2.10.3 Key Developments | | |
        4. 5.2.10.4 SWOT Analysis | | |
        5. 5.2.10.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY TYPE |
    8. 6.5 US MARKET ANALYSIS BY END USE |
    9. 6.6 US MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    10. 6.7 CANADA MARKET ANALYSIS BY APPLICATION |
    11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY END USE |
    13. 6.10 CANADA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION |
    16. 6.13 GERMANY MARKET ANALYSIS BY TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
    18. 6.15 GERMANY MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    19. 6.16 UK MARKET ANALYSIS BY APPLICATION |
    20. 6.17 UK MARKET ANALYSIS BY TYPE |
    21. 6.18 UK MARKET ANALYSIS BY END USE |
    22. 6.19 UK MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    23. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION |
    24. 6.21 FRANCE MARKET ANALYSIS BY TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
    26. 6.23 FRANCE MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    27. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION |
    28. 6.25 RUSSIA MARKET ANALYSIS BY TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    31. 6.28 ITALY MARKET ANALYSIS BY APPLICATION |
    32. 6.29 ITALY MARKET ANALYSIS BY TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY END USE |
    34. 6.31 ITALY MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    35. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION |
    36. 6.33 SPAIN MARKET ANALYSIS BY TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
    38. 6.35 SPAIN MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY APPLICATION |
    45. 6.42 CHINA MARKET ANALYSIS BY TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY END USE |
    47. 6.44 CHINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    48. 6.45 INDIA MARKET ANALYSIS BY APPLICATION |
    49. 6.46 INDIA MARKET ANALYSIS BY TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY END USE |
    51. 6.48 INDIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    52. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION |
    53. 6.50 JAPAN MARKET ANALYSIS BY TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
    55. 6.52 JAPAN MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    64. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION |
    65. 6.62 THAILAND MARKET ANALYSIS BY TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
    67. 6.64 THAILAND MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    68. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION |
    69. 6.66 INDONESIA MARKET ANALYSIS BY TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION |
    78. 6.75 BRAZIL MARKET ANALYSIS BY TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    81. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION |
    82. 6.79 MEXICO MARKET ANALYSIS BY TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
    84. 6.81 MEXICO MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORM |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY RADIOPHARMACEUTICAL FORM, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY RADIOPHARMACEUTICAL FORM, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY RADIOPHARMACEUTICAL FORM, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Diagnostic Imaging
  • Therapeutic Applications
  • Research Applications
  • Radiopharmaceutical Production

Healthcare By Type (USD Billion, 2025-2035)

  • Alpha Emitters
  • Beta Emitters
  • Gamma Emitters
  • Positron Emitters

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Centers
  • Research Institutions

Healthcare By Radiopharmaceutical Form (USD Billion, 2025-2035)

  • Injectable
  • Oral
  • Inhalation